ArticlePathogens & immunity2021
A Patient With Multiple Carbapenemase Producers Including an Unusual
Article in Pathogens & immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Within patient horizontal gene transfer dynamics of a blaEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Article
- Paradoxical carbapenemase activity detected by modified carbapenemase inactivation (mCIM) method inJournal of clinical microbiology · 2025Article
- Healthcare professionals challenged by 14 distinct carbapenemase-producing micro-organisms in a war-injured Ukrainian patient.Infection · 2025Article
- Plasmid diversity ofMicrobiology spectrum · 2025Article
- Genomic Characterization of NDM-1 Harboring Extensively-Drug ResistanceJournal of tropical medicine · 2025Article
- Genomic surveillance detects interregional spread of New Delhi metallo-beta-lactamase-1-producingEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Review
- Genome-Based Retrospective Analysis of aAntibiotics (Basel, Switzerland) · 2023Article
- A brief insight intoFrontiers in antibiotics · 2023Review
- Klebsiella pneumoniae ST147: and then there were three carbapenemases.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Article
- The Use of Long-Read Sequencing Technologies in Infection Control: Horizontal Transfer of aMicroorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients colonized with multiple species of carbapenemase-producing Enterobacterales (CPE) are increasingly observed. This phenomenon can be due to the high local prevalence of these pathogens, the presence of important host risk factors, and the great genetic promiscuity of some carbapenemase genes.
methodsWe analyzed 4 CPE (
resultsAll CPE presented high-level resistance to all aminoglycosides due to the expression of the
conclusionsThe characterization of the genetic organization of IncC-type plasmids harbored by 3 different species from the same patient offered insights into the evolution of these broad-host-range plasmids. Moreover, we characterized here the first complete genome sequence of a carbapenemase-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.